On Monday, SK revealed that it will spend $260 million to construct its fifth production site in its home country, this one ...

With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ...

Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Otsuka is once again on the PMCPA’s naughty list as the U.K. drug marketing regulatory body has for the second time this year ...